Apeloa

Apeloa Pharmaceutical Co., Ltd. was founded in 1989 as the pharmaceutical industry development platform of the renowned private enterprise Hengdian Group and is a main board listed company on the Shenzhen Stock Exchange. The company ranks among the top 40 pharmaceutical industrial enterprises in China, 25th in the "Top 100 Industrial Enterprises by Strength" (2nd in Zhejiang), 2nd in "API Exports" (1st in Zhejiang), among the top 5 CDMO companies on VCBeat, and within the "Top 100 Most Valuable Companies on China's Main Board" for the 14th consecutive year. It has also been selected as part of the second batch of Zhejiang Province's "Eagle Action" cultivation enterprises. In recent years, it has continuously received honors such as the "Industrial Powerhouse Contribution Award" of Dongyang City and the "Top 10 Taxpayers" in both Jinhua and Dongyang cities. After over 30 years of development, the company has developed strong capabilities in pharmaceutical R&D and manufacturing. It has established API technology centers, CDMO R&D centers, and drug research institutes in Hengdian headquarters, Shanghai, Boston (USA), and Hangzhou. Production bases have been built in Dongyang (Zhejiang), Weifang (Shandong), Dongzhi (Anhui), and Quzhou (Zhejiang), forming three core businesses: APIs, CDMO, and formulations. The company's API business has accumulated numerous technological achievements and talent resources, being the first in China’s API industry to continuously invest heavily in environmental governance, technological transformation, and product development. This has resulted in strong competitive advantages in cost, quality, EHS, and technology, establishing Apeloa as a leading enterprise in China's specialty API sector. As a core service provider in the global innovative pharmaceuticals industry chain for CDMO services, Apeloa has formed long-term strategic partnerships with top big pharma and biotech companies both domestically and internationally. Its business has grown steadily, maintaining a high growth rate. The formulation business adheres to differentiation and globalization strategies, achieving rapid development. Eight varieties have passed new category four approvals or consistency evaluations, creating well-known domestic brands such as "Baishixin" and "Tianliwei." The company has established integrated API-formulation and high technical barrier advantages, with its first high-end controlled-release generic drug already launched in the United States.